Blocklisting Six Monthly Return 31 December 2021 07:00:04 | RNS | 31.12.21 | 07:00:04 |
Total Voting Rights 31 December 2021 07:00:03 | RNS | 31.12.21 | 07:00:03 |
HUTCHMED Included in FTSE Russell Indexes 20 December 2021 07:00:08 | Reach | 20.12.21 | 07:00:08 |
Grant of Share Options and Awards under LTIP 15 December 2021 09:45:01 | RNS | 15.12.21 | 09:45:01 |
HMPL-523 Clinical Data Presented at ASH 14 December 2021 07:00:11 | Reach | 14.12.21 | 07:00:11 |
HUTCHMED Presents Data at ESMO Immuno-Oncology ‘21 10 December 2021 10:00:01 | Reach | 10.12.21 | 10:00:01 |
HUTCHMED Completes Planned Enrollment of FRESCO-2 06 December 2021 07:00:09 | Reach | 06.12.21 | 07:00:09 |
Updated NRDL to include ELUNATE and SULANDA 03 December 2021 07:00:04 | RNS | 03.12.21 | 07:00:04 |
Total Voting Rights 30 November 2021 08:30:05 | RNS | 30.11.21 | 08:30:05 |
HUTCHMED and AZ Initiate SACHI Phase 3 Trial 24 November 2021 07:00:04 | Reach | 24.11.21 | 07:00:04 |
HUTCHMED to Present Clinical Data at ASH 08 November 2021 07:00:09 | Reach | 08.11.21 | 07:00:09 |
HUTCHMED and AZ Initiate SAMETA Global P3 Trial 01 November 2021 07:00:14 | Reach | 01.11.21 | 07:00:14 |
| Total Voting Rights | RNS | 29.10.21 | 09:30:02 |
| HUTCHMED Initiates Phase III Trial of HMPL-523 | Reach | 28.10.21 | 07:00:04 |
| Grant of Awards under Long Term Incentive Plan | RNS | 20.10.21 | 09:30:03 |
Total Voting Rights 30 September 2021 09:30:07 | RNS | 30.09.21 | 09:30:07 |
HUTCHMED Highlights Presentations at CSCO 2021 29 September 2021 07:00:10 | Reach | 29.09.21 | 07:00:10 |
Closure of Non-Core OTC Joint Venture Divestment 29 September 2021 07:00:10 | Reach | 29.09.21 | 07:00:10 |
HUTCHMED Initiates Phase III Trial SURTORI-01 21 September 2021 07:00:10 | Reach | 21.09.21 | 07:00:10 |
Japan Bridging Study For Surufatinib Initiated 20 September 2021 07:00:09 | Reach | 20.09.21 | 07:00:09 |
